medigraphic.com
ISSN 0188-2198 (Print)

2017, Number 1

Next >>

Rev Mex Cardiol 2017; 28 (1)

Cardiac abnormalities in Trypanosoma cruzi seropositive patients in the State of Querétaro, México

Camacho-Calderón N, Villagrán-Herrera ME, Sánchez-Moreno M, Solís-Sainz JC, Hernández-Montiel HL, González-Pérez G, Dávila-Esquivel FJ, Linares A, de Diego CJA

Language: English
References: 24
Page: 4-9
PDF size: 218.01 Kb.


ABSTRACT

Background: Chagas disease is an endemic illness in the Americas and therefore constitutes a public health problem. An estimated 8 million people are infected and over 20 million live in areas at risk. In Mexico, the problem is under reported and no epidemiological data by the different States indicating true prevalence for this infection is available. During the chronic phase, 30% of infected patients may develop chagasic cardiomyopathy (CCM), characterized by different types of alterations of cardiac function. Objective: To describe cardiac abnormalities in Trypanosoma cruzi seropositive subjects in the endemic areas. Material and methods: This is a descriptive cross-sectional study with non-random sampling. In our project the endemic area was considered for Trypanosoma cruzi using the Epi Info statistical program (Stat Calc) to calculate the number of subjects to study by means of a sample of 1 033 subjects aged 2-90 years. Prior informed consent or parental consent, implementation of a survey, a 5 mL of blood sample free from anticoagulant was taken from the cubital vein to detect anti-Trypanosoma cruzi by ELISA, recombinant ELISA, hemagglutination indirect (HAI), indirect immunofluorescence (IFI) and Western blot (using the enzyme superoxide dismutase iron as antigen). Those subjects who were positive in two or more tests were chosen for electrocardiogram (EKG) and an echocardiogram (ECO) with portable devices. Results: Of the 1 033 participants, 84 between 6 and 88 years tested positive for Trypanosoma cruzi. In the analysis of data with echocardiograms and electrocardiograms, 47 subjects over 26 years (56%), presented right bundle branch block or left bundle block (RBBB/LBBB), changes in the diameters of the right ventricle or left ejection fraction accounting of 70%. In subjects under 26 years there were electrocardiographic changes (RBBB/LBBB). Conclusion: 8.13% were seropositive for Trypanosoma cruzi with ventricular conduction system and morphological alterations.


REFERENCES

  1. Rossi MA, Tanowitz HB, Malvestio LM, Celes MR, Campos EC, Blefari V et al. Coronary microvascular disease in chronic chagas cardiomyopathy including an overview on history, pathology, and other proposed pathogenic mechanisms. PLoS Negl Trop Dis. 2010; 4: e674.

  2. 2.Díaz L, Torres R, González CI. Expresión diferencial entre estadios de Trypanosoma cruzi en el aislamiento de un paciente con cardiomiopatía Chagásica crónica de zona endémica de Santander, Colombia. Biomédica. 2011; 31: 503-513.

  3. Schmunis GA, Zicker F, Pinheiro F, Brandling-Bennett D. Risk for transfusion-transmitted infectious diseases in Central and South America. Emerg Infect Dis. 1998; 4: 5-11.

  4. Dias JC, Schofield C. The evolution of chagas disease (American Trypanosomiasis) control after 90 years since Carlos Chagas discovery. Mem Inst Oswaldo Cruz. 1999; 94: 103-121.

  5. Ramsey JM, Ordoñez R, Cruz-Celis A, Alvear AL, Chavez V, Lopez R et al. Distribution of domestic triatominae and stratification of Chagas disease transmission in Oaxaca, Mexico. Med Vet Entomol. 2000; 14: 19-30.

  6. Ríos JF, Arboleda M, Montoya AN, Alarcón EP, Parra GJ. Probable brote de transmisión oral de enfermedad de Chagas en Turbo, Antioquia. Biomédica. 2011; 31: 185-195.

  7. Elizari MV. La miocardiopatia Chagásica. Perspectiva histórica. Medicina. 1999:59:25-40.

  8. Morris S, Tanowitz H, Wittner M, Bilezikian J. Pathophysiological insights into the cardiomyopathy of Chagas’ disease. Circulation. 1990; 82: 1900-1909.

  9. Curto de Casas S, Carcavallo UR, Galíndez GI. Factores bioclimáticos e zonas de vida. En: Carcavallo RU, Girón IG, Jurberg J, Lent H (editors). Atlas of Chagas’ disease vectors in the Americas. Rio de Janeiro, Brasil: Editora Fiocruz; 2000, pp. 800-838.

  10. Dias E, Laranja FS, Miranda A, Nobrega G. Chagas’ disease: a clinical, epidemiologic, and pathologic study. Circulation. 1956; 14: 1035-1060.

  11. Pinto Dias JC. Doenca de Chagas en Bambui, Minas Gerais, Brasil. Estudo clínico epidemiológico a partir da fase aguda entre 1940 e 1982. Thesis. Belo Horizonte. 1982.

  12. Puigbó JJ, Nava Rhode JR, García Barrios H, Gil Yépez C. Cuatro años de estudio longitudinal de una comunidad rural con endemicidad chagásica. Bol Oficina Sanitaria Panam (OSP). 1969; 66: 112-120.

  13. Tanowitz HB, Machado FS, Jelicks LA, Shirani J, Campos de Carvalho AC et al. Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease). Prog Cardiovasc Dis. 2009; 51: 524-539.

  14. Gimenez L, Mitelman J, Gonzalez C, Palacios K, Burgos AN. Alteraciones de la dispersión del QT y la fracción de eyección en pacientes chagásicos. Relampa. 2007; 20: 74-78.

  15. Sánchez B, Monteón V, Reyes PA, Espinoza B. Standardization of micro-enzyme-linked immunosorbent assay (elisa) and western blot for detection of Trypanosoma cruzi antibodies using extracts from Mexican strains as antigens. Arch Med Res. 2001; 32: 382-388.

  16. Villagrán ME, Marín C, Rodríguez-Gonzalez I, De Diego JA, Sánchez-Moreno M. Use of an iron superoxide dismutase excreted by Trypanosoma cruzi in the diagnosis of Chagas disease: Seroprevalence in rural zones of the state of Querétaro, México. Am J Trop Med Hyg. 2005; 73: 510-516.

  17. Rosenbaum MB, Alvarez AJ. The electrocardiogram in chronic Chagasic myocarditis. Am Heart J. 1955; 50: 492-527.

  18. Mancuso FJ, Almeida DR, Moisés VA, Oliveira WA, Mello ES, Poyares D et al. Left atrial dysfunction in chagas cardiomyopathy is more severe than in idiopathic dilated cardiomyopathy: A study with real-time three-dimensional echocardiography. J Am Soc Echocardiogr. 2011; 24: 526-532.

  19. Califf RM. Key issues for global cardiovascular medicine. Lancet. 2009; 374: 508-510.

  20. Gontijo ED, Galvão LM, Eloi-Santos S. Chagas disease: criteria of cure and prognosis. Mem Inst Oswaldo Cruz. 1999; 94: 357-362.

  21. Vallejo M, Montenegro P, Reyes PA. ¿Cuánto cuesta la atención de la cardiopatía chagásica crónica? Costos directos en un hospital de cardiología. Arch Cardiol Mex. 2002; 72: 129-137.

  22. Manzullo EC, Chuit R. Risk of death due to chronic chagasic cardiopathy. Mem Inst Oswaldo Cruz. 1999; 1: 317-320.

  23. Organización Mundial de la Salud (WHO). Atención primaria de salud, incluido el fortalecimiento de los sistemas de salud. Consejo Ejecutivo. 2009; Documento EB124.R8: 1-4.

  24. Rassi A Jr., Rassi A, Little WC. Chagas heart disease. Clin Cardiol. 2000; 23: 883-889.




2020     |     www.medigraphic.com